Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Response to Gutierrez et al. concerning the 5-year local recurrence-free survival (L-RFS) rate after a second breast conserving surgery and intraoperative radiotherapy (IORT).

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026

Same author

Economic evaluation of adjuvant chemotherapy for non-metastatic sarcoma using the real-world data from the French nationwide DEEPSARC study.

Journal of medical economics·2026

Same author

MiT fusions, TSC1-TSC2 divergence, and stem-like programs reveal distinct origins and vulnerabilities in PEComa.

Nature communications·2026

Same author

Hyperprogression after Immune Checkpoint Inhibitors: A Cloudy Phenomenon with Real-life Consequences.

Cancer communications (London, England)·2026

Same author

Overall survival of patients with localized soft tissue sarcoma treated with or without adjuvant chemotherapy (DEEPSARC): a real world nationwide retrospective cohort study in France.

EClinicalMedicine·2026

Same author

Beyond Surgical Margins: Fully Mature Tertiary Lymphoid Structures (fmTLSs) Are Predictive Biomarkers for Local Recurrence in Primary Soft-Tissue Sarcomas.

Cancers·2026

Same journal

Rule-Based Algorithm to Identify Recurrent Non-Hodgkin Lymphoma in Electronic Health Data.

JCO clinical cancer informatics·2026

Same journal

Bayesian Methods for Subgroup Efficacy and Safety: Application to Japanese Patients in JAVELIN Renal 101.

JCO clinical cancer informatics·2026

Same journal

Effect of a Multidimensional Digital Health Intervention on Quality of Life in Breast Cancer Survivors: A Randomized Controlled Trial.

JCO clinical cancer informatics·2026

Same journal

Can Small Open-Source Language Models With Retrieval-Augmented Generation Match GPT-4 Performance in Breast Cancer Clinical Decision Support?

JCO clinical cancer informatics·2026

Same journal

Machine Learning Algorithm for the Detection of Tumor Microsatellite Instability Based on Multiomics Biomarkers.

JCO clinical cancer informatics·2026

Same journal

Foundation Model-Driven Regions of Interest Classification and Renaming in Cancer Radiotherapy: A Customizable, Retraining-Free Workflow Across Institutions.

JCO clinical cancer informatics·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Nov 12, 2025

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

OSIRIS: A Minimum Data Set for Data Sharing and Interoperability in Oncology.

Julien Guérin¹, Yec'han Laizet^2,3, Vincent Le Texier⁴

¹Direction des Données, Institut Curie, Paris, France.

JCO Clinical Cancer Informatics

|March 15, 2021

Summary

This summary is machine-generated.

A French initiative developed the OSIRIS data model to accelerate clinical and genomic data sharing in oncology. This standardized approach enhances data interoperability for precision medicine research globally.

More Related Videos

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer

Published on: February 23, 2024

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Related Experiment Videos

Last Updated: Nov 12, 2025

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer

Published on: February 23, 2024

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Area of Science:

Oncology
Genomics
Precision Medicine
Health Informatics

Background:

Precision medicine initiatives in oncology generate vast amounts of clinical and genomic data globally.
Existing data sharing initiatives are limited, hindering collaborative research and advancements.

Purpose of the Study:

To improve and accelerate retrospective and prospective clinical and genomic data sharing in oncology.
To establish a national consensus on a minimal data set for oncology research.

Main Methods:

A multidisciplinary task force (SIRICs, Unicancer, university hospitals) developed the OSIRIS data model over five years.
Data structuring and technical solutions for collection and sharing were identified.
A consensus on a minimal data set was fostered through weekly scientific and technical meetings.

Main Results:

The OSIRIS set and event-based data model include 67 clinical and 65 omics items, capturing disease course.
The model is compatible with HL7 Fast Healthcare Interoperability Resources (FHIR) for maximum interoperability.
A proof-of-concept study validated the OSIRIS set and Common Data Model with 300 patients.

Conclusions:

The OSIRIS model provides a minimal set of clinical and genomic data to accelerate oncology data sharing.
The model's reliance on clear, formally defined terminologies can benefit the international research community.